Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple sclerosis.

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...

Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare ...

Biogen has secured European regulatory approval for a high-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy, or SMA. Biogen on Monday said the European ...

Shares of Biogen dipped after the biotechnology company said it expects to report a roughly $222 million pretax charge in the fourth quarter. Shares were down 5.9% to $167.88 on Wednesday morning. The ...